Zobrazeno 1 - 10
of 1 038
pro vyhledávání: '"immune-checkpoint inhibitor (ICI)"'
Publikováno v:
BMC Nephrology, Vol 25, Iss 1, Pp 1-8 (2024)
Abstract Background Immune checkpoint inhibitor (ICI) therapy has been widely investigated in urothelial carcinoma; however, the utility of ICI therapy in the treatment of organ transplant recipients with metastatic urothelial carcinoma (mUC) is uncl
Externí odkaz:
https://doaj.org/article/dfc19df11f5447029791b92b330cd80b
A multidimensional analysis of the impact of obesity on immune checkpoint inhibitor therapy efficacy
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background Obesity is a well-known risk factor for developing malignant tumors and promoting tumor cell growth and spread. However, recent studies have shown that obese cancer patients, who typically have a worse prognosis than nonobese canc
Externí odkaz:
https://doaj.org/article/37fbd49612c54ed8862173a8ed9906e0
Autor:
Ünal Metin Tokat, Ashkan Adibi, Esranur Aydın, Eylül Özgü, Şevval Nur Bilgiç, Onur Tutar, Merve Özbek Doğançay, İrem Demiray, Mutlu Demiray
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 5838-5849 (2024)
There is currently no effective treatment strategy for recurrent/metastatic adenoid cystic carcinoma (R/M ACC). Furthermore, recent single-agent and combination immunotherapy trials have failed in unselected ACC cohorts, unlike non-ACC salivary gland
Externí odkaz:
https://doaj.org/article/7094e808ef284ab8b902545349bfdba9
Autor:
Xiaoye Shi, Xiangshu Cheng, Aimin Jiang, Wenjie Shi, Lingxuan Zhu, Weiming Mou, Antonino Glaviano, Zaoqu Liu, Quan Cheng, Anqi Lin, Linhui Wang, Peng Luo
Publikováno v:
Advanced Science, Vol 11, Iss 47, Pp n/a-n/a (2024)
Abstract B cells are crucial component of humoral immunity, and their role in the tumor immune microenvironment (TME) has garnered significant attention in recent years. These cells hold great potential and application prospects in the field of tumor
Externí odkaz:
https://doaj.org/article/7bcc74f38e174216ac29240e18cb7d1d
Publikováno v:
Frontiers in Public Health, Vol 12 (2024)
BackgroundThe LUNAR trial demonstrated the significant efficacy and safety of Tumor Treating Fields (TTFields) plus standard-of-care (SOC) [immune checkpoint inhibitor (ICI) and docetaxel (DTX)] for patients with previously treated metastatic non-sma
Externí odkaz:
https://doaj.org/article/d329426478ea469898ab0c8893b0ba3e
Publikováno v:
Oral Oncology Reports, Vol 11, Iss , Pp 100564- (2024)
Advancements in Immune checkpoint inhibitor (ICI) treatment have greatly changed the way oropharyngeal squamous cell carcinoma (OPSCC) is treated. This paper examines the crucial advancements and their consequences for clinical practice. Initially, t
Externí odkaz:
https://doaj.org/article/8afde2a006654346a07c6554672ef9fb
Publikováno v:
Waike lilun yu shijian, Vol 29, Iss 02, Pp 106-113 (2024)
Progress in the systemic therapies, represented by the molecular target therapies and immune checkpoint inhibitors (ICIs), have significantly improved the prognosis of unresectable hepatocellular carcinoma (uHCC), but long term survial remains limitt
Externí odkaz:
https://doaj.org/article/f0bce1f678f64548bf7bbbd244ab9c4a
Autor:
Xiao-Tian Shen, Sun-Zhe Xie, Xin Zheng, Tian-Tian Zou, Bei-Yuan Hu, Jing Xu, Lu Liu, Yun-Feng Xu, Xu-Feng Wang, Hao Wang, Shun Wang, Le Zhu, Kang-Kang Yu, Wen-Wei Zhu, Lu Lu, Ju-Bo Zhang, Jin-Hong Chen, Qiong-Zhu Dong, Lu-Yu Yang, Lun-Xiu Qin
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-18 (2024)
Abstract Background Hepatocellular carcinoma (HCC) is closely associatedwith chronic liver diseases, particularly liver cirrhosis, which has an altered extracellular matrix (ECM) composition. The influence and its mechanism of the cirrhotic-ECM on th
Externí odkaz:
https://doaj.org/article/11f20552fc3944ccb8a7f193cd109f08
Autor:
Abdulmohammad Pezeshki, John C. Cheville, Angela B. Florio, Bradley C. Leibovich, George Vasmatzis
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundOnly 20 percent of renal and bladder cancer patients will show a significant response to immune checkpoint inhibitor (ICI) therapy, and no test currently available accurately predicts ICI response.MethodsWe developed an “immunotumoroid”
Externí odkaz:
https://doaj.org/article/7218c9713dc1428da8affaa6bf70d426
Autor:
Faizah M. Alotaibi, Ibrahim Abdullah S. Albalawi, Amna M. Anis, Hawazin Alotaibi, Seham Khashwayn, Kanan Alshammari, Jaffar A. Al-Tawfiq
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
BackgroundImmune checkpoint inhibitors (ICI) have improved overall survival in patients with different cancer types. However, treatment efficacy varies between patients depending on several factors. Recent research suggested that antibiotic-induced d
Externí odkaz:
https://doaj.org/article/9a0187f6780c4ecdaaaa975bfc46bfbf